Replies to post #16173 on Algernon Pharmaceuticals Inc (AGNPF)

[GVX808]

…and away we go!
AGNPF broke through the 200-day MA like a rocket, with positive results from the full data set of its Ifenprodil Phase 2a for IPF and chronic cough treatment.

Algernon as a company is making some good moves. The NIA coverage is certainly helping tremendously too! Paid or not, they have been the catalyst we have needed for a loooong time to interest new investors and get the share price to a respectable level.

Great ELP video! ;)

GLTA!